Highlights

New Study: Zotatifin Enhances CAR-T Cell Therapy Against Lymphoma

New research from the University of Miami Miller School of Medicine suggests that our clinical-stage molecule, Zotatifin - a first-in-class flavagline - enhances the efficacy of CAR-T cell therapy. The study indicates that Zotatifin makes lymphoma cells more susceptible to being killed, primarily by disrupting the NRF2 stress response pathway.

Read original article

​

Researchers Learn How a Drug Called Zotatifin Kills Cancer Cells

UCSF researchers have discovered how the experimental cancer drug zotatifin kills tumor cells by attacking two major cancer-promoting pathways at once. This dual-action mechanism explains its potency and could lead to more effective combination treatments.

Read original article

​

Zotatifin Triplet Gains FDA Fast Track Status in ER+/HER2- Breast Cancer

The FDA has granted Fast Track designation to a triplet therapy containing zotatifin for patients with advanced ER+/HER2- breast cancer, accelerating its development and review. This status is intended to promote quicker patient access to promising new treatments.

Read original article

​

Positive data from trial of zotatifin for Covid-19

The cancer drug, zotatifin, is repurposed for a Phase 2 trial to treat hospitalized COVID-19 patients. The study investigates if the drug can inhibit the viral replication of SARS-CoV-2.

Read original article

​